Nervous Disorder TRIZ Cases

Engineered antibodies bind CXCR4 to reduce metastasis while minimizing systemic toxicity through targeted delivery.

N1-substituted N4-pyridin-2-ylmethyl butane-1,4-diamine compounds selectively chelate copper ions to treat Wilson's disease with fewer adverse effects.

Administering a leptin composition reduces tau phosphorylation, addressing ineffective current therapies that fail to modulate accumulation.

Non-cleavable linker conjugates maintain cytotoxic potency while reducing plasma clearance and toxicity compared to cleavable alternatives.

Replacing carboxylic acid moieties with bioisosteric groups in DHODH inhibitors reduces URAT-1 interactions and hematuria while maintaining inhibitory activity.

Recombinant AAV2 vectors deliver ApoE ε2 nucleic acids into ependymal cells, enabling secretion into cerebrospinal fluid to bypass the blood-brain barrier.

Administering adenosine A2A and NMDA NR2B receptor antagonists reduces dyskinesia and abnormal involuntary movements while potentiating L-Dopa efficacy.

Combining anti-phosphorylcholine antibodies with biologic agents modulates immune responses to enhance therapeutic efficacy.

Engineered BTLA agonist antibodies mimic HVEM binding to resolve cross-species applicability limits in autoimmune disease treatment.

A crosslinked polymer network forms a porous scaffold to support neuronal growth.

A diagnostic method measures BLyS and APRIL heterotrimer levels in serum samples to identify autoimmune disease markers.

Curcumin protects phosphatidylserine sodium salt from oxidation and degradation through antioxidant activity.

A pharmaceutical composition combines Panax ginseng, Wolfiporia cocos, nattokinase, and dietary fibers to enhance gut microbiota diversity.

Selective compounds inhibit Toll-like receptor signaling pathways to treat inflammatory diseases without compromising immune response.

Integrating CB1 inhibitors with antidepressants reduces withdrawal symptoms and relapse risk while minimizing depression and suicide liability.

Indolyl hydroxamates counteract irreversible neuronal loss by promoting protection and motor recovery, resolving therapeutic insufficiency.

Mulberry and Poria cocos extract inhibits amyloid-beta plaques and tau phosphorylation to protect nerve cells.

Mikania guaco extracts inhibit choline metabolism by gut microbiota, lowering trimethylamine production linked to cardiovascular disease risk.

Replacing ethanol with diol and sugar alcohol carriers eliminates burning sensation while maintaining absorption efficiency in oral sprays.

Chiral synthesis of triazolopyrazines improves enantiomeric purity to resolve safety and CNS penetrability trade-offs.

Amino acid substitutions create a protease-resistant modified beta-subunit homodimer to degrade GM2 gangliosides in enzyme replacement therapy.

Cotinine activates alpha7 nicotinic receptors to stimulate neurogenesis, reducing chemotherapy-induced cognitive impairment and depressive-like behaviors.

Macrocyclic tetrapeptides antagonize the kappa opioid receptor, resolving safety concerns from prolonged small molecule blockade.

Selective T-type calcium channel antagonists rescue long-term potentiation deficits, improving cognitive function while reducing side effects.

Selective GluN2A-NMDAR antagonists mitigate neuroinflammation and improve functional outcomes by blocking homocysteine-induced signaling pathways.

Extract from vaccinia-inoculated inflamed tissue increases proteoglycan and collagen synthesis in chondrocytes to regenerate extracellular matrices.

Administering ghrelin to ameliorate neurological and gastrointestinal symptoms in Rett Syndrome patients.

Local botulinum toxin injection targets unmyelinated C-fibers to reduce excess glutamate and Substance P, treating arrhythmia without motor side effects.

Combining clavulanic acid with valproic acid triggers hippocampal neuroregeneration to treat refractory epilepsy.

Codon-optimized rAAV vectors deliver SLC13A5 polypeptides to address genetic deficiencies causing epileptic encephalopathy.

A p75 extracellular domain peptide neutralizes amyloid-beta toxicity to protect neurons from degeneration.

A dual GLP-1 GLP-2 agonist peptide activates both receptor types to enhance intestinal barrier function and glucose control.

Modified Factor VII polypeptides incorporate heterologous Gla domains to increase phospholipid affinity and coagulant activity.

Specific structural modifications enable quinazoline derivatives to penetrate the blood-brain barrier, treating central nervous system metastases.

Nano-sized gas bubbles overcome intestinal mucous membrane barriers to accelerate microbial engraftment speed and improve colonization ratios.

Phosphatidylcholine mediates cannabinoid delivery across the blood-brain barrier, reducing side effects while treating addiction.

Segmented amlodipine and losartan granules prevent gelation at low pH, maintaining high dissolution rates and storage stability.

Administering low-dose fenfluramine minimizes cardiac complications and severe side effects while achieving significant seizure reduction in Dravet Syndrome.

Flavour agent coating reduces plant protein off-flavors and enables shorter frying times.

Segmented peptide inhibitors bind JNK2 to reduce NMDA-induced glutamate release, lowering neurotoxicity without broad receptor antagonism.

IgG antibody mediates erythropoietin transport across the blood-brain barrier, achieving brain delivery while minimizing systemic plasma exposure.

Segmented fatty acid compositions stabilize blood ketone levels, reducing gastrointestinal upset while maintaining therapeutic efficacy.